1. Visceral Pain in Preterm Infants with Necrotizing Enterocolitis: Underlying Mechanisms and Implications for Treatment.
- Author
-
Ten Barge JA, van den Bosch GE, Slater R, van den Hoogen NJ, Reiss IKM, and Simons SHP
- Subjects
- Humans, Infant, Newborn, Analgesics therapeutic use, Animals, Pain Management methods, Enterocolitis, Necrotizing drug therapy, Enterocolitis, Necrotizing physiopathology, Enterocolitis, Necrotizing complications, Enterocolitis, Necrotizing therapy, Visceral Pain drug therapy, Visceral Pain physiopathology, Visceral Pain etiology, Visceral Pain therapy, Infant, Premature
- Abstract
Necrotizing enterocolitis (NEC) is a relatively rare but very severe gastrointestinal disease primarily affecting very preterm infants. NEC is characterized by excessive inflammation and ischemia in the intestines, and is associated with prolonged, severe visceral pain. Despite its recognition as a highly painful disease, current pain management for NEC is often inadequate, and research on optimal analgesic therapy for these patients is lacking. Insight into the mechanisms underlying intestinal pain in infants with NEC-visceral pain-could help identify the most effective analgesics for these vulnerable patients. Therefore, this comprehensive review aims to provide an overview of visceral nociception, including transduction, transmission, modulation, and experience, and discuss the implications for analgesic therapy in preterm infants with NEC. The transmission of visceral pain differs from that of somatic pain, contributing to the diffuse nature of visceral pain. Studies evaluating the effectiveness of analgesics for treating visceral pain in infants are scarce. However, research in visceral pain models highlights agents that may be particularly effective for treating visceral pain based on their mechanisms of action. Further research is necessary to determine whether agents that have shown promise for treating visceral pain in preclinical studies and adults are effective in infants with NEC as well., Competing Interests: Declarations. Funding: No specific financial support was received for this study. Competing Interests: J.t.B. is funded by the Friends of Sophia Foundation (in Dutch: Vrienden van het Sophia; grant number WEL21-07). R.S. is funded via a Senior Wellcome Fellowship awarded to grant number 207457/Z/17/Z. N.v.d.H. is funded by an Alberta Innovates Postdoctoral Fellowship. None of the authors have any conflicts of interest to disclose. Ethics Approval: Not applicable. Consent: Not applicable. Data Availability Statement: Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study. Code Availability: Not applicable. Author Contributions: J.t.B. drafted the manuscript. G.v.d.B., R.S., N.v.d.H., I.R., and S.S. revisited the manuscript critically for important intellectual content. All authors have approved the final version of the manuscript., (© 2025. The Author(s).)
- Published
- 2025
- Full Text
- View/download PDF